CLAIM AMENDMENTS

1-24. (canceled)

25. (currently amended): A pharmaceutical composition for parenteral administration, comprising particulate delivery vehicles having associated therewith at least a first antineoplastic agent and a second antineoplastic agent, wherein said first and second agents are in a mole ratio which exhibits a non-antagonistic cytotoxic or cytostatic effect in an *in vitro* assay, over at least 20% of the concentration range over which the fraction of cells affected is 0.2-0.8; and wherein said first and second agents are associated with the delivery vehicles to maintain [[a]] said non-antagonistic ratio in the blood [[on]] for at least one hour after administration,

wherein said delivery vehicles comprise

liposomes, and/or

lipid micelles, and/or

block copolymer micelles, and/or

polymer microparticles, and/or

polymer nanoparticles, and/or

polymer lipid hybrid systems, and/or

derivatized single chain polymers.

26. (previously presented): The composition of claim 25 wherein said delivery vehicles are 4 to 6,000 nm in diameter.

27. (previously presented): The composition of claim 25 wherein said delivery vehicles have a mean diameter of between 4.5 and 500 nm.

28. (previously presented): The composition of claim 27 wherein said vehicles have a mean diameter of less than 250 nm.

29. (previously presented): The composition of claim 25 wherein said delivery vehicles are from 4μm to 50μm in diameter.

30. (previously presented): The composition of claim 25 wherein said delivery vehicles comprise liposomes.

31. (previously presented): The composition of claim 25 wherein said first and second agents are co-encapsulated.

32-38. (canceled)

39. (currently amended): The composition of ~~claim 38~~ claim 25
wherein the first agent is irinotecan and the second agent is 5-FU or FUDR, or
wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR, or
wherein the first agent is idarubicin and the second agent is AraC or FUDR, or
wherein the first agent is oxaliplatin and the second agent is 5-FU or FUDR, or
wherein the first agent is irinotecan and the second agent is cisplatin (or carboplatin), or
wherein the first agent is gemcitabine and the second agent is cisplatin (or carboplatin), or
wherein the first agent is methotrexate and the second agent is 5-FU or FUDR, or
wherein the first agent is paclitaxel and the second agent is cisplatin (or carboplatin), or
wherein the first agent is etoposide and the second agent is cisplatin (or carboplatin), or
wherein the first agent is docetaxel or paclitaxel and the second agent is doxorubicin, or
wherein the first agent is doxorubicin and the second agent is vinorelbine, or
wherein the first agent is carboplatin and the second agent is vinorelbine, or
wherein the first agent is 5-FU or FUDR and the second agent is gemcitabine.

40. (previously presented): The composition of claim 39 wherein the first agent is irinotecan and the second agent is 5-FU or FUDR or
wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR.

41. (currently amended): A method to prepare a composition of claim 25, which method comprises

~~a) determining in a relevant cell culture assay for cytotoxic or cytostatic activity a mole ratio of said first and~~

~~second agent which is non-antagonistic over at least 5% of the concentration range over which greater than 1% of cells are affected by said ratio of agents, and~~

~~b) encapsulating~~ stably associating with said particulate delivery vehicles a mole ratio of agents that has been determined to [[be]] exhibit a non-antagonistic cytotoxic or cytostatic effect in ~~step a)~~ an *in vitro* assay over at least 20% of the concentration range over which the fraction of cells affected is 0.2-0.8;

wherein said stable association is such that said ratio is maintained in the blood for at least one hour after administration.

42-44. (canceled)

45. (currently amended): The method of claim 41, wherein said ~~determining~~ ratio has been determined in an assay that employs testing at least one ratio of said agents at a multiplicity of concentrations and applying an algorithm to calculate a synergistic, additive, or antagonistic effect for said ratio over a range of concentrations.

46. (previously presented): The method of claim 45 which employs testing a multiplicity of ratios, and wherein said algorithm is the Chou-Talalay median effect method.

47-50. (canceled)

51. (currently amended): A method to treat a neoplastic disease condition in a subject which method comprises administering to the subject an effective amount of the composition of claim 25.

52. (previously presented): The method of claim 51 wherein the subject is a human.

53. (previously presented): The method of claim 51 wherein the subject is a non-human mammal or avian.

54. (new): The method of claim 41 wherein the delivery vehicles are liposomes.

55. (new): The method of claim 54

wherein the first agent is irinotecan and the second agent is 5-FU or FUDR, or

wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR, or

wherein the first agent is idarubicin and the second agent is AraC or FUDR, or

wherein the first agent is oxaliplatin and the second agent is 5-FU or FUDR, or

wherein the first agent is irinotecan and the second agent is cisplatin (or carboplatin), or

wherein the first agent is gemcitabine and the second agent is cisplatin (or carboplatin), or

wherein the first agent is methotrexate and the second agent is 5-FU or FUDR, or

wherein the first agent is paclitaxel and the second agent is cisplatin (or carboplatin), or

wherein the first agent is etoposide and the second agent is cisplatin (or carboplatin), or

wherein the first agent is docetaxel or paclitaxel and the second agent is doxorubicin, or

wherein the first agent is doxorubicin and the second agent is vinorelbine, or

wherein the first agent is carboplatin and the second agent is vinorelbine, or

wherein the first agent is 5-FU or FUDR and the second agent is gemcitabine.

56. (new): The method of claim 55 wherein the first agent is irinotecan and the second agent is 5-FU or FUDR or

wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR.